A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
NCT05948865
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer
- Cancer, Lung
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Last updated on ClinicalTrials.gov
- March 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
- UCLA Hematology/Oncology - Santa Monica · Santa Monica, CA
Colorado · 1
- Sarah Cannon Research Institute (SCRI) at HealthONE · Denver, CO
Florida · 2
- AdventHealth Cancer Institute · Celebration, FL
- Florida Cancer Specialists · Sarasota, FL
New Hampshire · 1
- Dartmouth Hitchcock Medical Center · Lebanon, NH
Pennsylvania · 1
- Fox Chase Cancer Center · Philadelphia, PA
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 1
- NEXT Dallas · Dallas, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.